ID   IRAK2_HUMAN             Reviewed;         625 AA.
AC   O43187; B4DQZ6; Q08AG6; Q5K546;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 2.
DT   10-MAY-2017, entry version 157.
DE   RecName: Full=Interleukin-1 receptor-associated kinase-like 2;
DE            Short=IRAK-2;
GN   Name=IRAK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLU-431.
RA   Rosati O., Martin M.U.;
RT   "Identification of Exon 13 and the 3'UTR region of human IRAK-2 and
RT   characterisation of the full length gene.";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-590, FUNCTION, TISSUE SPECIFICITY,
RP   INTERACTION WITH TRAF6; MYD88 AND IL1R1, AND VARIANT GLU-431.
RC   TISSUE=Endothelial cell;
RX   PubMed=9374458; DOI=10.1126/science.278.5343.1612;
RA   Muzio M., Ni J., Feng P., Dixit V.M.;
RT   "IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of
RT   IL-1 signaling.";
RL   Science 278:1612-1615(1997).
RN   [5]
RP   FUNCTION.
RX   PubMed=10383454; DOI=10.1074/jbc.274.27.19403;
RA   Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., Cao Z.;
RT   "IRAK-M is a novel member of the Pelle/interleukin-1 receptor-
RT   associated kinase (IRAK) family.";
RL   J. Biol. Chem. 274:19403-19410(1999).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-144, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (3.40 ANGSTROMS) OF 2-112.
RX   PubMed=20485341; DOI=10.1038/nature09121;
RA   Lin S.-C., Lo Y.-C., Wu H.;
RT   "Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R
RT   signalling.";
RL   Nature 465:885-890(2010).
RN   [9]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-43; TYR-47; VAL-99; THR-147;
RP   GLY-214; LEU-249; VAL-392; THR-421; GLU-431; VAL-439; ASN-469; ILE-503
RP   AND TRP-566.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Binds to the IL-1 type I receptor following IL-1
CC       engagement, triggering intracellular signaling cascades leading to
CC       transcriptional up-regulation and mRNA stabilization.
CC       {ECO:0000269|PubMed:10383454, ECO:0000269|PubMed:9374458}.
CC   -!- SUBUNIT: Interacts with MYD88. IL-1 stimulation leads to the
CC       formation of a signaling complex which dissociates from the IL-1
CC       receptor following the binding of PELI1.
CC       {ECO:0000269|PubMed:9374458}.
CC   -!- INTERACTION:
CC       P10398:ARAF; NbExp=2; IntAct=EBI-447733, EBI-365961;
CC       P68467:K7R (xeno); NbExp=2; IntAct=EBI-447733, EBI-8022707;
CC       Q6PDS3:Sarm1 (xeno); NbExp=2; IntAct=EBI-447733, EBI-6117196;
CC       P46977:STT3A; NbExp=2; IntAct=EBI-447733, EBI-719212;
CC       Q13148:TARDBP; NbExp=2; IntAct=EBI-447733, EBI-372899;
CC       P58753:TIRAP; NbExp=2; IntAct=EBI-447733, EBI-528644;
CC       Q9H0E2:TOLLIP; NbExp=2; IntAct=EBI-447733, EBI-74615;
CC       Q5D1E8:ZC3H12A; NbExp=2; IntAct=EBI-447733, EBI-747793;
CC   -!- TISSUE SPECIFICITY: Expressed in spleen, thymus, prostate, lung,
CC       liver, skeletal muscle, kidney, pancreas and peripheral blood
CC       leukocytes. {ECO:0000269|PubMed:9374458}.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily. {ECO:0000305}.
CC   -!- CAUTION: Asn-335 is present instead of the conserved Asp which is
CC       expected to be an active site residue. This enzyme has been shown
CC       to be catalytically inactive. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ496794; CAD43180.3; -; mRNA.
DR   EMBL; AK299033; BAG61108.1; -; mRNA.
DR   EMBL; BC125184; AAI25185.1; -; mRNA.
DR   EMBL; AF026273; AAB87669.1; -; mRNA.
DR   CCDS; CCDS33697.1; -.
DR   RefSeq; NP_001561.3; NM_001570.3.
DR   UniGene; Hs.449207; -.
DR   PDB; 3MOP; X-ray; 3.40 A; K/L/M/N=2-112.
DR   PDBsum; 3MOP; -.
DR   ProteinModelPortal; O43187; -.
DR   SMR; O43187; -.
DR   BioGrid; 109865; 34.
DR   DIP; DIP-31800N; -.
DR   IntAct; O43187; 30.
DR   MINT; MINT-97184; -.
DR   STRING; 9606.ENSP00000256458; -.
DR   iPTMnet; O43187; -.
DR   PhosphoSitePlus; O43187; -.
DR   BioMuta; IRAK2; -.
DR   EPD; O43187; -.
DR   MaxQB; O43187; -.
DR   PaxDb; O43187; -.
DR   PeptideAtlas; O43187; -.
DR   PRIDE; O43187; -.
DR   DNASU; 3656; -.
DR   Ensembl; ENST00000256458; ENSP00000256458; ENSG00000134070.
DR   GeneID; 3656; -.
DR   KEGG; hsa:3656; -.
DR   UCSC; uc003bve.2; human.
DR   CTD; 3656; -.
DR   DisGeNET; 3656; -.
DR   GeneCards; IRAK2; -.
DR   HGNC; HGNC:6113; IRAK2.
DR   HPA; CAB013483; -.
DR   HPA; HPA050520; -.
DR   MIM; 603304; gene.
DR   neXtProt; NX_O43187; -.
DR   OpenTargets; ENSG00000134070; -.
DR   PharmGKB; PA29913; -.
DR   eggNOG; KOG1187; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00530000063073; -.
DR   HOGENOM; HOG000113102; -.
DR   HOVERGEN; HBG052145; -.
DR   InParanoid; O43187; -.
DR   KO; K04731; -.
DR   OMA; LSEWDWM; -.
DR   OrthoDB; EOG091G0YKT; -.
DR   PhylomeDB; O43187; -.
DR   TreeFam; TF328924; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-937042; IRAK2 mediated activation of TAK1 complex.
DR   Reactome; R-HSA-937072; TRAF6 mediated induction of TAK1 complex.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975155; MyD88 dependent cascade initiated on endosome.
DR   Reactome; R-HSA-975163; IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation.
DR   Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane.
DR   SignaLink; O43187; -.
DR   EvolutionaryTrace; O43187; -.
DR   GeneWiki; IRAK2; -.
DR   GenomeRNAi; 3656; -.
DR   PRO; PR:O43187; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000134070; -.
DR   CleanEx; HS_IRAK2; -.
DR   Genevisible; O43187; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0002756; P:MyD88-independent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0070423; P:nucleotide-binding oligomerization domain containing signaling pathway; TAS:Reactome.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0034162; P:toll-like receptor 9 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR033611; IRAK2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   PANTHER; PTHR24419:SF30; PTHR24419:SF30; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    625       Interleukin-1 receptor-associated kinase-
FT                                like 2.
FT                                /FTId=PRO_0000086032.
FT   DOMAIN       13     94       Death.
FT   DOMAIN      210    489       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     216    224       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     337    340       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     237    237       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     144    144       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT      43     43       R -> Q (in dbSNP:rs34945585).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041342.
FT   VARIANT      47     47       S -> Y (in dbSNP:rs11465864).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_030527.
FT   VARIANT      99     99       I -> V (in dbSNP:rs55898544).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041343.
FT   VARIANT     147    147       R -> T (in dbSNP:rs56053222).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041344.
FT   VARIANT     214    214       R -> G (in dbSNP:rs35060588).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041345.
FT   VARIANT     249    249       S -> L (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041346.
FT   VARIANT     392    392       L -> V (in dbSNP:rs3844283).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_030528.
FT   VARIANT     421    421       P -> T (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041347.
FT   VARIANT     431    431       D -> E (in dbSNP:rs708035).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9374458,
FT                                ECO:0000269|Ref.1}.
FT                                /FTId=VAR_030529.
FT   VARIANT     439    439       L -> V (in dbSNP:rs11465927).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_030530.
FT   VARIANT     469    469       D -> N (in dbSNP:rs56242986).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041348.
FT   VARIANT     503    503       L -> I (in dbSNP:rs9854688).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_030531.
FT   VARIANT     566    566       R -> W (in dbSNP:rs55740652).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041349.
FT   VARIANT     574    574       D -> H (in dbSNP:rs11465930).
FT                                /FTId=VAR_030532.
FT   HELIX         5      7       {ECO:0000244|PDB:3MOP}.
FT   HELIX        10     16       {ECO:0000244|PDB:3MOP}.
FT   TURN         17     22       {ECO:0000244|PDB:3MOP}.
FT   HELIX        25     32       {ECO:0000244|PDB:3MOP}.
FT   TURN         33     36       {ECO:0000244|PDB:3MOP}.
FT   HELIX        39     47       {ECO:0000244|PDB:3MOP}.
FT   HELIX        48     50       {ECO:0000244|PDB:3MOP}.
FT   HELIX        56     65       {ECO:0000244|PDB:3MOP}.
FT   TURN         66     68       {ECO:0000244|PDB:3MOP}.
FT   HELIX        72     76       {ECO:0000244|PDB:3MOP}.
FT   TURN         77     81       {ECO:0000244|PDB:3MOP}.
FT   HELIX        84     87       {ECO:0000244|PDB:3MOP}.
FT   TURN         88     91       {ECO:0000244|PDB:3MOP}.
SQ   SEQUENCE   625 AA;  69433 MW;  715C954BC9452710 CRC64;
     MACYIYQLPS WVLDDLCRNM DALSEWDWME FASYVITDLT QLRKIKSMER VQGVSITREL
     LWWWGMRQAT VQQLVDLLCR LELYRAAQII LNWKPAPEIR CPIPAFPDSV KPEKPLAASV
     RKAEDEQEEG QPVRMATFPG PGSSPARAHQ PAFLQPPEED APHSLRSDLP TSSDSKDFST
     SIPKQEKLLS LAGDSLFWSE ADVVQATDDF NQNRKISQGT FADVYRGHRH GKPFVFKKLR
     ETACSSPGSI ERFFQAELQI CLRCCHPNVL PVLGFCAARQ FHSFIYPYMA NGSLQDRLQG
     QGGSDPLPWP QRVSICSGLL CAVEYLHGLE IIHSNVKSSN VLLDQNLTPK LAHPMAHLCP
     VNKRSKYTMM KTHLLRTSAA YLPEDFIRVG QLTKRVDIFS CGIVLAEVLT GIPAMDNNRS
     PVYLKDLLLS DIPSSTASLC SRKTGVENVM AKEICQKYLE KGAGRLPEDC AEALATAACL
     CLRRRNTSLQ EVCGSVAAVE ERLRGRETLL PWSGLSEGTG SSSNTPEETD DVDNSSLDAS
     SSMSVAPWAG AATPLLPTEN GEGRLRVIVG READSSSEAC VGLEPPQDVT ETSWQIEINE
     AKRKLMENIL LYKEEKVDSI ELFGP
//
